Open account
Sign up/Log in
FACTBOX-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Madrigal Pharmaceuticals' drug wins first US approval for fatty liver disease NASH. Madrigal's drug is the first to win regulatory approval to treat a serious type of liver disease. Other companies are also developing treatments for the disease. The race to tap a multi-billion dollar market is intensifying.
Reuters · 03/14 20:09
FACTBOX-Novo Nordisk brings new contender in race for blockbuster obesity drugs
Novo Nordisk and Eli Lilly are the leaders in the weight-loss drug market. The market is estimated to be worth $100 billion by the end of the decade. Novo's drug amycretin helped obese patients achieve 13.1% weight loss after 12 weeks.
Reuters · 03/07 12:45
UPDATE 1-European shares fall over lacklustre Chinese stimulus, economic data in focus
European shares fall over lacklustre Chinese stimulus, economic data in focus. The pan-European STOXX 600 was down 0.3% after settling just below all-time highs on Monday. China pledges to transform its economy failed to impress investors. Euro zone and U.S. Economic data due today.
Reuters · 03/05 09:35
EUROPE RESEARCH ROUNDUP-Direct Line Insurance, Hammerson, Mercedes Benz Group AG
Analysts revise their ratings and price targets on several European companies. Direct Line Insurance, Hammerson and Mercedes Benz Group AG among those. Campari, Airbus and BAE Systems among companies to see share price moves. European markets are closed on Wednesday for the World Cup in Brazil.
Reuters · 02/28 07:21
FACTBOX-Drugmakers deepen efforts to tap into booming market for obesity drugs
Viking Therapeutics says its experimental drug helped patients with obesity achieve "significant" weight loss in a mid-stage study. Novo Nordisk and Eli Lilly are so far the leaders in the weight-loss drug market. The market is estimated to be worth $100 billion by the end of the decade.
Reuters · 02/27 18:15
BUZZ-Altimmune up after rival Zealand's obesity drug shows promise in fatty-liver patients
Altimmune up after rival Zealand's obesity drug shows promise in fatty-liver patients. Shares of drug developer Altimmune rise 13.8% to $10.47 in premarket trading. Zealand Pharma reports "groundbreaking" mid-stage trial results for an experimental drug for a type of fatty liver.
Reuters · 02/26 14:17
UPDATE 1-Commodity-linked stocks drag European equities lower
European shares fall on Monday, led by a decline in commodity-linked stocks. The pan-European STOXX 600 was down 0.4%, on track for the biggest one day drop in two weeks. Basic resources sub-index leads losses as oil and gas stocks fall. Euro zone, U.S. Inflation data in focus this week.
Reuters · 02/26 10:18
UPDATE 1-Zealand Pharma shares surge on liver disease drug trial data
Zealand Pharma shares surge on liver disease drug trial data. Zealand shares hit a record high and were the best performer on the STOXX Europe 600. The company is developing an experimental obesity treatment with Boehringer Ingelheim. The drug meets its primary and key secondary endpoints in the treatment of fatty liver.
Reuters · 02/26 09:10
Webull offers Zealand Pharma A/S stock information, including NASDAQ: ZEAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZEAL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading ZEAL stock methods without spending real money on the virtual paper trading platform.